India’s first indigenous mRNA vaccine manufacturing facility has begun production at the Serum Institute campus in Pune, making India one of only six countries with the capability to produce mRNA vaccines domestically. The facility, built with technology transfer support from WHO’s mRNA Technology Transfer Hub, has an initial capacity of 500 million doses per year.
The plant’s first product will be an updated COVID-19 booster targeting the latest variants, followed by mRNA vaccines for influenza, malaria, and tuberculosis that are currently in clinical trials.
Health experts have described the development as a major step towards pandemic preparedness, reducing India’s dependence on imported vaccine technology during future health emergencies.
About The Author
